TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Positivity for NTCVAG04 in vaginal swabs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects achieving 'excellent' or 'good' cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of subjects finding the agent easy to take or tolerable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of participants with recurrence of anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants with anal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (cmax) of GLPG3067
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero until 24 hours post-dose (AUC0-24h) of GLPG3067
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero until 72 hours post-dose (AUC0-72h) of GLPG3067
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic Pain Diagnostic Questionnaire (DN4) Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dependence of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Successful Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical stress
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of participants achieving two-year failure
Endpoint domain: Mortality/survival
Primary endpoint: Vaccine response for pertussis and anti-poliovirus types 1, 2, and 3 titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Radiation Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cerebral Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 1-year Relapse-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in total score of Parkinson's Disease Questionnaire-8
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Satiety levels following the consumption of buckwheat and fava bean-based diets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hourly hunger scores analysed using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of reoperations
Endpoint domain: Adverse events/effects
Primary endpoint: maximal tolerance dose (MTD) of RC48-ADC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Kisspeptin 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of miR-324-3p
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Behavior Checklist Internalizing Scale at 5 Years of Age
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Behavior Checklist Externalizing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knee Range of Motion Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Resistive Index (RRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global Disease Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Radiological healing progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative duration of unscheduled hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cumulative duration of scheduled hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: therapeutic equivalence of imiquimod cream in treating AK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 12 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 4 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity Score of Moderate or Severe Hot Flashes After 12 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of Radioiodine Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACIT-Fatigue Change From Baseline to 13-weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphology of electroencephalogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in impedance cardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cutaneous microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antimicrobial effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CGI-I scale rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants with Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pharmacogenomics Knowledge Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effects on individual organ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Past-month (30-day) Marijuana Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of Past-month (30-day) Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in pre-dose FEV1 at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in 2-hour post-dose FEV1 at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in capillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body movements during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in expression of selected biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg wound assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cmax - Maximum Observed Concentration - Pravastatin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of classification analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment emergent adverse events (TEAE) of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Normalized current signal from the CGM devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically driven Target vessel Revascularization (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacokinetics of ganciclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in immune status to yellow fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of treatment-associated grade 1-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic analysis of plasma YF476 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Side Effect Management
Endpoint domain: Adverse events/effects
Primary endpoint: Morisky Measurement Adherence Scale
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Development of oral tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to hospital for bronchiolitis
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Clinical Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to evacuation of the short-term implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity and specificity of INSTI™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Month Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: 3-Month Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volumetric change of periapical lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Reachable Workspace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of leptomeningeal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time needed to access the peritoneal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: numbers of trials till the good peritoneal access achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Implementation of evidence-based guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of yearly height velocity (ΔHV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in Reactive Hyperemia Index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Requirement for additional uterotonic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wall shear stress in AVFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Oscillatory shear index in AVFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary patency of the hypogastric side branch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: changes in metabolomic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Episcleral Venous Pressure (EVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of basiliximab
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of and dependence on feeding tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in standard scores for each domain on the Vineland-II
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Patients Developing a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: CD86 Receptor Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Participants With Accelerated Phase or Blast Phase CML Who Achieve a Meaningful Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Participants With Chronic Phase CML Who Achieve a Meaningful Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Adverse Experiences (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate response during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen uptake during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberrant Behavior Checklist Hyperactivity Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ALT Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in AST Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change From Baseline in PANSS Total Score at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Dystonia Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Antiretroviral tissue localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25-hydroxyvitamin-D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours Post-dose - Metabolite A77 1726
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetic Influx Constant (Ki)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HBV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of antibodies against adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with periodontal problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of aesthetic, functional and biological properties for each base material restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients free from progression
Endpoint domain: Mortality/survival
Primary endpoint: violent behavior as assessed by MOAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychiatry symptoms as assessed by PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood levels of EPA, DHA, NE, DA, and 5-HT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: density of 5-HT1A receptor in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean electrical diaphragmatic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time-to-crusting of vesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total difficulty score of the SDQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Shoulder internal rotation and horizontal adduction range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thoracoabdominal asynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vaginal bleeding during the 1st 24 hours postoperative
Endpoint domain: Adverse events/effects
Primary endpoint: Voluntary Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrichment of spirulina ß-carotene and vitamin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of heart rate (HR) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of systolic blood pressure (SBP) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of diastolic blood pressure (DBP) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified Parkinson Activity Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time from decision for endovascular treatment to groin puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Conners Parent and Teacher Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of patients with IMP-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Vestibular Evoked Myogenic Potentials (VEMPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hospital-acquired VRE-colonization and/or infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VO2 peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dry Mouth as an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Dry Mouth as an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Troponin-T release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline liver fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Healing of the Corneal Epithelial Defect at Day 14 ± 1 in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events Following Application of the Investigational Product in All Subjects
Endpoint domain: Adverse events/effects
Primary endpoint: Area of pin prick hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plaque superficial irregularities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mu rhythm desynchronization (alpha band power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Remission Rate (ORR)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in ECG Variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes in Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Griffiths Mental Development Scale (GMDS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Confirmed Response (Complete Response or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Response for Participants With Confirmed Response (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progression or Death
Endpoint domain: Mortality/survival
Primary endpoint: Infant urinary iodine concentration (UIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant dried blood spot thyroglobulin (DBS-Tg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall liking of drug formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Formulation preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of 8-oxo-deoxyguanine in 24 hour-urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes